TradingKey

On October 15 Eastern Time, CoreWeave (CRWV) fell by as much as 9.5% in early Thursday trading before recovering its morning drop of over 9%. A sell-off over the past four consecutive trading days has erased more than $10 billion from CRWV's market capitalization. As of Thursday, the stock's cumulative loss for the week exceeded 22%. As of press time, CRWV shares reversed course to rise 1.6% to $66.83.

• BlackRock reported strong third-quarter revenue growth exceeding Wall Street expectations. • Net client inflows drove total assets under management to historic highs. • Analysts raised price targets following robust financial results and strategic execution.

• KLA Corporation faced downward pressure amid a broader semiconductor sector sell-off. • Macroeconomic inflation concerns and high interest rates drove technology valuation reassessments. • KLA reports annual revenue of $13.58B and net profit of $4.83B.

• Netflix announced plans to reduce approximately 1,000 corporate positions globally. • Jefferies reaffirmed a Buy rating with a premium price target. • Netflix reported an annual revenue of $45.18B and net profit of $10.98B.

• Gilead partnered with Vir Biotechnology to develop next-generation oncology therapies. • Strong HIV franchise performance and bullish analyst coverage drove momentum. • The stock closed higher despite intraday volatility and profit-taking.

• SanDisk faced downward volatility due to competition, profit-taking, and semiconductor sector weakness. • The MACD indicates a sell signal, while the Williams %R suggests oversold conditions. • Annual revenue reached $20.25 billion with a net profit of $11.43 billion.

• AstraZeneca partnered with insitro in a deal valued up to $1.5 billion. • The company reported an annual revenue of $58.74 billion and net profit of $10.22 billion. • Multiple analysts rated the stock as Buy with an average price target of $210.65.

• Amgen's upward momentum is driven by positive analyst upgrades and raised earnings estimates. • Progress in the R&D pipeline, especially MariTide, has strongly buoyed market sentiment. • The company reported $36.75B in annual revenue and $7.71B in net profit.

• Arista Networks faced downward pressure as investors engaged in profit-taking after recent rallies. • Senior management executed stock sales under pre-arranged 10b5-1 trading plans. • Analysts maintain a Buy rating with an average price target of $242.07.

• Macroeconomic headwinds and hotter inflation triggered a broader semiconductor sector pullback. • Custom ASIC volume scaling creates temporary gross margin compression and profit-taking. • Institutional research remains constructive due to structural long-term growth drivers.

On October 15, US Eastern Time, Micron (MU) shares reversed losses to turn higher, after falling over 6% intraday to a low of $858, hitting their lowest level since August 11. Recently, new technological advancements by ChangXin Memory Technologies (CXMT) sparked market concerns over the DRAM competitive landscape. However, both HSBC and Daiwa believe the short-term impact may be overestimated, while Elon Musk's affirmation of Micron's pricing strategy offers another perspective on its long-term customer relationships.

• Applied Materials faced downward pressure due to uncertain semiconductor capital expenditure timelines. • Management withheld near-term wafer fab equipment spending targets, creating investor friction. • The stock recorded $28.37B in annual revenue and $7.00B in net profit.

• UnitedHealth raised its full-year adjusted earnings guidance for the third consecutive time. • The medical care ratio improved through tighter cost management and disciplined pricing. • Latest annual revenue reached $447.93B, ranking first in the industry.

• Home Depot surged due to institutional buying and positive Wall Street analyst upgrades. • Strong operational fundamentals and contractor expansion supported revenue stability and market share. • Annual revenue reached $164.68B, with net profit totaling $14.16B, ranking first.

• Wall Street downgraded Dell due to slowing enterprise artificial intelligence adoption concerns. • Silver Lake Partners triggered market anxiety through significant insider share sales. • Macroeconomic inflation fears and high valuations pressured technology sector equities downward.

• FDA approved Rhapsido for symptomatic dermographism and advanced pipeline candidates. • Institutional capital flowed into Novartis ahead of the upcoming earnings. • Novartis reported annual revenue of $56.33B and net profit of $13.98B.

On October 15, Eastern Time, SpaceX (SPCX) stock tumbled to as low as $140.66, down over 20% from its recent high of $176.42 on October 6 and hitting its lowest level since early September. However, the sharp pull-back in stock price does not necessarily signal a simultaneous deterioration in fundamentals; the decline is more likely dragged down by a broader sell-off in AI hardware stocks. Meanwhile, speculation surrounding a potential merger between SpaceX and Tesla (TSLA) continues to heat up, which could serve as the latest catalyst for near-term stock price recovery.

• Rising capital expenditures and AI investments raised concerns about near-term profitability constraints. • Third-quarter vehicle deliveries declined year-over-year amid pricing pressures and softening Chinese demand. • Technical indicators show a neutral MACD and RSI, with Williams %R suggesting selling.

• Cisco disclosed an actively exploited zero-day security vulnerability in its software. • Expanded valuation multiples and profit-taking contributed to the stock's downside pressure. • Analysts expressed concerns regarding rising memory costs and near-term margin compression.

• AMD shares declined amid a broad sell-off in semiconductor and AI sectors. • Higher Treasury yields and inflation data spurred risk-off sentiment in technology stocks. • Technical indicators show neutral conditions alongside an oversold Williams %R level.